139934-80-8

Usage

Uses

Used in Medicinal Chemistry:
4-[(2R,4S,5S)-5-[(tert-butoxycarbonyl)amino]-4-hydroxy-2-[(1S)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]carbamoyl-6-phenylhexyl]phenoxyacetic acid is used as a compound with potential applications in medicinal chemistry due to its unique structure and multiple functional groups.
Used in Drug Development:
In the pharmaceutical industry, 4-[(2R,4S,5S)-5-[(tert-butoxycarbonyl)amino]-4-hydroxy-2-[(1S)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]carbamoyl-6-phenylhexyl]phenoxyacetic acid is used as a compound with potential for drug development, given its complex structure and the presence of various functional groups that may be exploited for therapeutic purposes.

Upstream product

• 140468-56-0 (L)-phenylalanine <2(R)-hydroxy-1(S)-indanyl>amide 
• 138499-15-7 [(1S,2S,4R)-1-Benzyl-5-(4-benzyloxy-phenyl)-2-(tert-butyl-dimethyl-silanyloxy)-4-((1S,2R)-2-hydroxy-indan-1-ylcarbamoyl)-pentyl]-carbamic acid tert-butyl ester 
• 126410-44-4 L-692048 
• 138498-62-1 N-(2(R)-hydroxy-1(S)-indanyl)-5(S)-[1,1-dimethylethoxy-carbonylamino]-4(S)-hydroxy-6-phenyl-2(R)-(4-hydroxyphenylmethyl) hexanamide 
• 126410-42-2 5(S)-<(tert-butyloxycarbonyl)amino>-4(S)-<(tert-butyldimethylsilyl)oxy>-6-phenyl-2(R)-<<4-(benzyloxy)phenyl>methyl>hexanoic acid 
• 142526-87-2 5(S)-(Boc-amino)-4(S)-hydroxy-6-phenyl-2(R)-[(p-benzyloxyphenyl)methyl]-hexanoic acid 
• 140468-58-2 [(R)-1-((1S,2R)-2-Hydroxy-indan-1-ylcarbamoyl)-2-phenyl-ethyl]-carbamic acid tert-butyl ester 
• 7480-35-5 trans-1-aminoindan-2-ol 
• 7480-35-5 (+/-)-cis-1-amino-indan-2-ol 
• 140468-61-7 {4-[(2R,4S,5S)-5-tert-Butoxycarbonylamino-4-hydroxy-2-((1S,2R)-2-hydroxy-indan-1-ylcarbamoyl)-6-phenyl-hexyl]-phenoxy}-acetic acid ethyl ester 
• 7480-35-5 (1S,2R)-1-amino-2-indanol 
• 140468-55-9 2-phenyl-3a,8a-dihydro-8(H)-indeno<1,2-d>oxazole 

Relevant academic research and scientific papers

Synthesis and antiviral activity of a series of HIV-1 protease inhibitors with functionality tethered to the P1 or P1'phenyl substituents: X-ray crystal structure assisted design

By tethering of a polar hydrophilic group to the P1 or P1' substituent of a Phe-based hydroxyethylene isostere, the antiviral potency of a series of HIV protease inhibitors was improved. The optimum enhancement of anti-HIV activity was observed with the 4-morpholinylethoxy substituent. The substituent effect is consistent with a model derived from inhibitor docked in the crystal structure of the native enzyme. An X-ray crystal structure of the inhibited enzyme determined to 2.25 A verifies the modeling predictions.